USPTO serial 79309391
NAVIGATION DRUG
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 24, 2022
- Examiner
- FALK, JONATHAN ROBERT
- Law office
- TMO LAW OFFICE 111
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with NAVIGATION DRUG?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Sapporo-shi, Hokkaido, JP
Sapporo-shi, Hokkaido, JP
Sapporo-shi, Hokkaido, JP
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Mary Margaret L. O'Donnell
Mary Margaret L. O'Donnell Blue Filament Law PLLC700 E. Maple RoadSuite 450Birmingham, MI 48009Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Reagents for research purposes; reagents for chemical analyses other than for medical or veterinary purposes; reagents for use in scientific apparatus for chemical or biological analysis; diagnostic reagents for scientific or research use; diagnostic reagents and preparations, except for medical or veterinary use; chemicals, namely, chemicals used in industry, sulfonates, chemicals for use in agriculture, except fungicides, herbicides, insecticides and parasiticides | ACTIVE | — |
| 005 | Pharmaceutical preparations and substances for the diagnosis and treatment, and the prevention of breast, brain, colorectal and gastro-intestinal cancer; pharmaceutical preparations and substances used for detecting body fluids; pharmaceutical preparations and substances used for detecting pancreatic fluids; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of cancer; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of digestive system disorders; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of bone diseases; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of hyperlipidemia diseases; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of gastrointestinal diseases; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of hypoglycemia; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of sarcoma; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of immune system diseases and disorders; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of hypertension; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of respiratory diseases and disorders; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of skin disorders; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of multiple sclerosis; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of cardiovascular diseases; pharmaceutical preparations for treating peripheral nervous system disorders; pharmaceutical preparations for treating central nervous system disorders; diagnostic biomarker reagents for medical purposes; veterinary diagnostic reagents; fluorescent diagnostic reagents for veterinary purposes; fluorescent diagnostic test reagents for veterinary purposes; diagnostic test reagents for medical purposes; fluorescent diagnostic test reagents for medical purposes; fluorescent diagnostic reagents for medical purposes; pharmaceutical preparations and other preparations for destroying vermin, fungicides, herbicides; fluorescent medical diagnostic reagents; chemical reagents for veterinary purposes; fluorescent chemical reagents for veterinary purposes; chemical reagents for medical purposes; fluorescent chemical reagents for medical purposes; reagents for medical purposes; fluorescent reagents for medical purposes; medical diagnostic reagents and assays for testing of body fluids; medical diagnostic reagents and analysis samples for testing of body fluids; medical fluorescent diagnostic reagents and assays for testing of body fluids; medical fluorescent diagnostic reagents and analysis samples for testing of body fluids; medical clinical diagnostic reagents; fluorescent reagents for the clinical diagnosis; therapeutic drugs and agents, namely, agents for the treatment of malignant tumors | ACTIVE | — |
| 044 | Medical testing services using fluorescent reagents for diagnostic or treatment purposes; medical analysis services for the analysis, diagnosis, and treatment of patients using fluorescent reagents provided by medical laboratories; medical analysis for the diagnosis and treatment of persons; medical diagnostic services; medical evaluation of breast, brain, colorectal and gastro-intestinal cancer; medical diagnostic services using fluorescent reagents; medical evaluation services of breast, brain, colorectal and gastro-intestinal cancer using fluorescent reagents; diagnosis of diseases; diagnosis of diseases using fluorescent reagents; diagnosis of cancer; diagnosis of cancer using fluorescent reagents; medical testing services relating to the diagnosis and treatment of disease; medical testing services relating to the diagnosis and treatment of disease using fluorescent reagents; medical analysis services relating to the diagnosis and treatment of disease using fluorescent reagents provided by medical laboratories; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical analysis for the diagnosis of cancer; cancer screening services; cancer screening services using fluorescent reagents; medical services for the analysis of samples taken from patients provided by medical laboratories; fluorescence imaging examination for the medical diagnosis or treatment; providing information in the field of cancer prevention, screening, diagnosis and treatment; providing medical information; providing medical information on diagnosis using fluorescent reagents; providing information on medical diagnosis using fluorescent reagents; medical analysis for the diagnosis of cancer using fluorescent reagents; rental of medical apparatus and installations; rental of medical diagnostic apparatus and installations; rental of medical diagnostic apparatus using fluorescent reagents and medical apparatus and installations using fluorescent reagents | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Goryo Chemical, Inc.
- Other trademarks owned by Goryo Chemical, Inc.
- Other trademarks owned by Goryo Chemical, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 044
- Similar marks named NAVIGATION DRUG
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 2, 2023 | NURC | NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED | — |
| Mar 28, 2023 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Mar 28, 2023 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Mar 23, 2023 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Oct 3, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 13, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 13, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Aug 24, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 7, 2022 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| May 24, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| May 24, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 22, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 22, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 20, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Feb 2, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 2, 2022 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Feb 2, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 18, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 13, 2022 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Jan 13, 2022 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Dec 22, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 22, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 22, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 21, 2021 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Dec 21, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 21, 2021 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Dec 21, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 21, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 21, 2021 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Aug 1, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 12, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 12, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 3, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jun 25, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 24, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 16, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 27, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 23, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 22, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |